Moderna

Today we announced that the first participants in the U.S. and UK have been dosed in a Phase 3 study of our investigational mRNA-based H5 pandemic influenza vaccine candidate, mRNA-1018. In December 2025, CEPI (Coalition for Epidemic Preparedness Innovations) and Moderna announced that CEPI will invest up to $54.3 million to help advance mRNA-1018 to licensure. Read more: https://lnkd.in/e3M76Knw

Today we announced that three abstracts on our investigational mRNA therapeutics have been accepted for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, which will be held May 29 – June 2 in Chicago, IL.    Read more about the presentation details: https://lnkd.in/eSQDfFBq

Today we announced that the European Commission (EC) has granted marketing authorization for mCOMBRIAX® (mRNA-1083), our mRNA combination vaccine for active immunization for the prevention of influenza disease and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older.   Read more: https://lnkd.in/ewjgdAJ4

Earlier today, we presented data from a Phase 1/2 study of mRNA-4359, an investigational cancer antigen therapy, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, held from April 17-22, 2026. Watch our latest IR Insights video with Dr. David Berman, Moderna’s new Chief Development Officer, to learn more about the presentation and Dr. Berman’s journey to Moderna. https://lnkd.in/etJ-3Pau

We announced today that we will present data from a Phase 1/2 study of mRNA-4359, an investigational cancer antigen therapy, at the American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA, on April 17-22, 2026. The U.S. FDA has granted Fast Track designation for mRNA-4359 in combination with pembrolizumab for the treatment of checkpoint inhibitor refractory unresectable or metastatic melanoma with PD-L1+ (TPS≥1%). Read more: https://lnkd.in/eDP8BdcR

We’re proud to celebrate Tracey Franklin, our Chief People and Digital Technology Officer, on being named to Reuters Events’ Trailblazing Women in Pharma 2026 list.   Tracey is recognized for redefining how people, culture and digital innovation come together at Moderna—using AI, data and digital platforms to reshape how work gets done and empower employees to deliver on the promise of mRNA medicines.   She joins an outstanding group of leaders across the industry driving meaningful change. Congratulations, Tracey, on this well-deserved recognition.

We announced today that we will present late-breaking oral presentations on revaccination data for both mRNA-1010, our investigational seasonal influenza vaccine, and for mRESVIA® (mRNA-1345), our mRNA respiratory syncytial virus (RSV) vaccine, at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, Germany, on April 17-21, 2026.    Learn more: https://lnkd.in/e55_BS46   #ESCMIDGlobal2026 

Rare Disease Day is a moment to recognize the more than 300 million people worldwide living with a rare disease — and the continued need for innovation. For one family, that reality is deeply personal. Sarahya and Xayvior were both diagnosed as infants with methylmalonic acidemia (MMA), a rare, life-threatening genetic disease that can trigger dangerous metabolic crises and requires constant vigilance. Their childhoods have included feeding tubes, frequent hospital visits and ongoing care, but they are much more than their diagnosis. 🎥 Watch their full story: https://lnkd.in/ezSnPfTU.

Today we announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending marketing authorization in the European Union for mCOMBRIAX® (mRNA-1083), Moderna’s combination vaccine indicated for active immunization for the prevention of influenza and COVID-19 caused by SARS-CoV-2 in individuals 50 years of age and older. Read more: https://lnkd.in/eyZzxcr6.

Today we announced that, in response to a prior Refusal-to-File letter, we engaged with the U.S. Food and Drug Administration (FDA) in a Type A meeting and proposed a revised regulatory approach for our investigational seasonal influenza vaccine candidate, mRNA-1010. Read more: https://lnkd.in/eJRpqCtN